8-K: Sanuwave Health Reports Q2 2026 Results, Faces Revenue Dip

Sanuwave Health announced its second quarter 2026 financial results, reporting a 3% decrease in revenue to $9.7 million, alongside a shift to an operating loss.

Summary

• Sanuwave Health reported Q2 2026 revenues of $9.7 million, a 3% decrease from $10.1 million in Q2 2025.
• Gross margin decreased to 76.2% in Q2 2026 from 78.1% in Q2 2025.
• The company reported an operating loss of $0.3 million for Q2 2026, compared to an operating income of $1.4 million in Q2 2025.
• Net loss for Q2 2026 was $0.7 million, a change from a net income of $0.6 million in Q2 2025.
• Adjusted EBITDA decreased to $1.2 million in Q2 2026 from $3.2 million in Q2 2025.
• Ultramist applicator revenue increased by 13% year-over-year, reaching $7.3 million, and accounted for approximately 75% of total revenue.
• System sales were negatively impacted by CMS reimbursement changes and the emergence of a market for used Ultramist systems.
• The company is withdrawing its previously issued fiscal year 2026 guidance due to market conditions and CMS reimbursement developments.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to declining revenues, reduced gross margins, and a shift from operating income to a loss, despite strong applicator sales.

Positives

• Ultramist applicator unit volumes increased by 13% sequentially from Q1 2026 and 27% year-on-year.
• Ultramist applicator revenue increased by 13% to $7.3 million in Q2 2026 compared to $6.4 million in Q2 2025.
• Applicator sales accounted for approximately 75% of revenues, exceeding the target range of 60-65%, indicating strong demand for consumables.
• Revenue for Q2 2026 ($9.7 million) was slightly above the high end of the revised guidance provided on June 16, 2026.

Negatives

• Total revenue for Q2 2026 decreased by 3% to $9.7 million from $10.1 million in Q2 2025.
• Gross margin percentage decreased to 76.2% in Q2 2026 from 78.1% in Q2 2025.
• The company reported an operating loss of $0.3 million in Q2 2026, a significant decline from an operating income of $1.4 million in Q2 2025.
• Net loss for Q2 2026 was $0.7 million, compared to a net income of $0.6 million in Q2 2025.
• Adjusted EBITDA fell to $1.2 million in Q2 2026 from $3.2 million in Q2 2025.
• Sales of Ultramist systems decreased to 82 units in Q2 2026 from 116 units in Q2 2025.

Risks

• CMS reimbursement changes and recoupments around allografts are negatively impacting customer behavior and capital budgets.
• The emergence of a significant market for used Ultramist systems is leading to lower than expected sales of new systems.
• The proposed CMS rule for 2027 reimbursement for code 97610 is not what the company was hoping for and presents potential challenges.
• The company's ability to manage its capital resources is a factor.
• Competition within the advanced wound care market poses a risk.

Future Outlook

Sanuwave is withdrawing its previously issued fiscal year 2026 guidance due to market conditions and CMS reimbursement developments. The company will not provide further guidance until there is greater clarity on these topics and expects to reassess after the CMS publishes its final rule, anticipated in the fourth quarter of 2026.

Management Comments

• "2026 has been a challenging period for the advanced wound care market. Despite this, Q2 was another all time record for Ultramist applicator unit volumes, which increased 13% sequentially from Q1 and 27% year on year."
• "We take this to be a strong sign of ongoing demand for and confidence in the Ultramist system as a treatment modality for complex and non-healing wounds."
• "As previously discussed, system sales were negatively impacted in the quarter both by ongoing stress in our customer base from CMS reimbursement changes and recoupments around allografts and by the emergence of a significant market for used Ultramist systems, which led to lower than expected sales by the Company."
• "The silver lining on that seems to be that demand for systems during the quarter remained fairly robust if one includes our estimation of used sales on top of those sold by the Company."
• "Moving on to the CMS proposed rule for 2027 97610 reimbursement announced this July, obviously, this is neither what we were hoping for nor what we expected, especially in light of having just had a 14% increase in our proposed reimbursement rate in the HOPD setting come out a couple of weeks prior."
• "While Sanuwave wholeheartedly supports CMSs goal of accurate, data driven payment, we have some material disagreements with the methodology, process, and assumptions utilized by CMS in their proposed rule for 2027 and, as one might expect, will be active in the comment period to seek reconsideration before a final rule is issued."
• "Our goal in this comment period will be to ensure that the data that drives this decision is both accurate and complete and that it reflects the full practitioner costs (and the systemic benefits) of providing treatment under 97610, which is, of course, the intent of these rules."
• "We believe that we have a strong case to make and, with the support of a great many customers and academic institutions and thought leaders who have reached out with gracious offers to help, we plan to make it vigorously."

Industry Context

StockSavvy.ai notes that the advanced wound care market is experiencing challenges, particularly related to reimbursement policies from entities like CMS. The emergence of a secondary market for medical devices can also impact new sales, a trend observed by Sanuwave. The company's focus on applicator sales as a revenue driver highlights a common strategy in device companies to secure recurring revenue.

Stakeholder Impact

• Shareholders may be concerned by the decline in revenue, profitability, and the withdrawal of guidance.
• Customers may be impacted by CMS reimbursement changes and the availability of used systems, affecting their purchasing decisions.
• Suppliers may see reduced demand for certain components if system sales continue to be impacted.

Next Steps

• A business update conference call will occur on August 7, 2026, at 8:30 am EST.
• The company will actively participate in the CMS comment period to seek reconsideration of the proposed rule for 2027 reimbursement.
• The company expects to reassess providing guidance after CMS publishes its final rule, anticipated in Q4 2026.

Key Dates

Recommendation

The company is facing significant headwinds with declining revenue, reduced margins, and a shift to an operating loss, compounded by uncertainty around CMS reimbursement. While applicator sales show strength, the overall financial performance and withdrawn guidance warrant a cautious 'hold' stance until clarity emerges on reimbursement and market dynamics.

Keywords

wound care, Ultramist, applicator revenue, CMS reimbursement, financial results, operating loss, Adjusted EBITDA, regenerative medicine